Justina Vasiliauskas, OD
Optometrist · West Palm Beach, FLNPI 1952900805
Payments from drug & device makers
Across 207 payments — averaging $52.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Bausch & Lomb Americas Inc.$2K
- AbbVie$1K
- Tarsus Pharmaceuticals, Inc.$926
- Sun Pharmaceutical Industries Inc.$713
- Johnson & Johnson Vision Care, Inc.$691
- plus $2K from 20 others
What the payments were for
- Travel & lodging$7557%
- Food & beverage$9,97892%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 36 | $3,025 |
| Bausch & Lomb Americas Inc. | 23 | $1,994 |
| AbbVie(2 entities) | 36 | $1,041 |
| Tarsus Pharmaceuticals, Inc. | 18 | $926 |
| Sun Pharmaceutical Industries Inc. | 20 | $713 |
| Johnson & Johnson Vision Care, Inc. | 14 | $691 |
| Mallinckrodt Hospital Products Inc. | 11 | $346 |
| Harrow Eye, LLC | 6 | $314 |
| Sight Sciences, Inc. | 3 | $306 |
| Amgen | 2 | $250 |
| Dompe US, Inc. | 9 | $245 |
| Glaukos Corporation | 2 | $170 |
| Thea Pharma Inc. | 1 | $103 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| Oyster Point Pharma, Inc. | 4 | $79 |
| Eyevance Pharmaceuticals LLC | 1 | $76 |
| Genentech USA, Inc. | 3 | $67 |
| Rxsight Inc | 2 | $66 |
| Astellas Pharma US Inc | 2 | $64 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| Novartis | 2 | $41 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Biotissue Holdings Inc. | 1 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Coopervision Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,809 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 22 | $1,014,152 |
| RestasisCyclosporine | 118 | $108,318 |
| LumiganBimatoprost | 142 | $57,701 |
| MieboPerfluorohexyloctane/Pf | 64 | $47,548 |
| XdemvyLotilaner | 24 | $45,475 |
| VyzultaLatanoprostene Bunod | 63 | $27,032 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $26,439 |
| CequaCyclosporine | 38 | $24,800 |
| CombiganBrimonidine Tartrate/Timolol | 59 | $19,394 |
| RhopressaNetarsudil Mesylate | 25 | $13,295 |
| Cyclosporine | 20 | $10,292 |
| Alphagan PBrimonidine Tartrate | 22 | $6,308 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 56 | $4,954 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 101 | $3,335 |
| Prednisolone Acetate | 79 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $245 | $1,014,15222 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,041 | $191,721341 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $1,994 | $74,580127 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $926 | $45,47524 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $20 | $39,73486 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $713 | $24,80038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,166 optometrist providers in Florida.
Other optometrist in West Palm Beach
- April JasperWest Palm Beach$781K
- Michael KynnJacksonville$4.5M
- Christine HalodaJacksonville$3.1M
- Bradley GieddWinter Park$2.5M
- Christopher PearsonLongwood$2.5M
- Mark PerryOrlando$1.6M
- Bryan StamJacksonville Beach$1M
- Oksana SovaJacksonville$841K
- James HoffmanOrange Park$795K
- Jerry RobbenSt Augustine$663K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.